Viral and bacterial infection elicit distinct changes in plasma lipids in febrile children

Xinzhu Wang¹, Ruud Nijman², Stephane Camuzeaux³, Caroline Sands³, Heather Jackson², Myrsini Kaforou², Marieke Emonts^{4,5,6}, Jethro Herberg², Ian Maconochie⁷, Enitan D Carrol^{8,9,10}, Stephane C Paulus^{9,10}, Werner Zenz¹¹, Michiel Van der Flier^{12,13}, Ronald de Groot¹³, Federico Martinon-Torres¹⁴, Luregn J Schlapbach¹⁵, Andrew J Pollard¹⁶, Colin Fink¹⁷, Taco T Kuijpers¹⁸, Suzanne Anderson¹⁹, Matthew Lewis³, Michael Levin², Myra McClure¹ on behalf of EUCLIDS consortium*

1. Jefferiss Research Trust Laboratories, Department of Medicine, Imperial College London
2. Section of Paediatrics, Department of Medicine, Imperial College London
3. National Phenome Centre and Imperial Clinical Phenotyping Centre, Department of Surgery and Cancer, IRDB Building, Du Cane Road, Imperial College London, London, W12 0NN, United Kingdom
4. Great North Children's Hospital, Paediatric Immunology, Infectious Diseases & Allergy, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom.
5. Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom
6. NIHR Newcastle Biomedical Research Centre based at Newcastle upon Tyne Hospitals NHS Trust and Newcastle University, Newcastle upon Tyne, United Kingdom
7. Department of Paediatric Emergency Medicine, St Mary's Hospital, Imperial College NHS Healthcare Trust, London, United Kingdom
8. Institute of Infection and Global Health, University of Liverpool, Liverpool, United Kingdom
9. Department of Infectious Diseases, Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom

10. Liverpool Health Partners, Liverpool, United Kingdom
11. Department of General Paediatrics, University of Graz, Graz, Austria
12. Pediatric Infectious Diseases and Immunology, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, The Netherlands
13. Pediatric Infectious Diseases and Immunology, Amalia Children's Hospital, and Section Pediatric Infectious Diseases, Laboratory of Medical Immunology, Department of Laboratory Medicine, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands
14. Pediatrics Department, Translational Pediatrics and Infectious Diseases Section, Santiago de Compostela, Spain
15. Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia
16. Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom
17. Micropathology Ltd, University of Warwick, Warwick, United Kingdom
18. Division of Pediatric Hematology, Immunology and Infectious diseases, Emma Children's Hospital Academic Medical Center, Amsterdam, The Netherlands.
19. Medical Research Council Unit Gambia, Banjul, The Gambia.

* Members of the EUCLIDS Consortium are listed in the appendix

Funding

This work was partially supported by the European Seventh Framework Programme for Research and Technological Development (FP7) under EUCLIDS Grant Agreement no. 279185ICED: The Research was supported by the National Institute for Health Research Biomedical Research Centre based at Imperial College

This work was further supported by the Medical Research Council and National Institute for Health Research [grant number MC_PC_12025] through funding for the MRC-NIHR National

53 Phenome Centre, infrastructure support was provided by the National Institute for Health
54 Research (NIHR) Biomedical Research Centre (BRC) at Imperial NHS Healthcare Trust.
55 This paper is independent research funded by the NIHR Imperial BRC.

56

Abstract

Fever is the most common reason that children present to Emergency Departments in the UK. Clinical signs and symptoms suggestive of bacterial infection are often non-specific, and there is no definitive test for the accurate diagnosis of infection. As a result, many children are prescribed antibiotics often unnecessarily, while others with life-threatening bacterial infections can remain untreated. The 'omics' approaches to identifying biomarkers from the host-response to bacterial infection are promising. In this study, lipidomic analysis was carried out with plasma samples obtained from febrile children with confirmed bacterial infection (n=20) and confirmed viral infection (n=20). We show for the first time that bacterial and viral infection elicit distinct changes in the host lipidome. Glycerophosphoinositol, sphingomyelin, lysophosphatidylcholine and cholesterol sulfate were increased in the confirmed virus infected group, while fatty acids, glycerophosphocholine, glycerophosphoserine, lactosylceramide and bilirubin were increased in cases with confirmed bacterial infection. A combination of three lipids achieved the area under the receiver operating characteristic (ROC) curve of 0.918 (95% CI 0.835 to 1). This pilot study demonstrates the potential of metabolic biomarkers to assist clinicians in distinguishing bacterial from viral infection in febrile children, to facilitate effective clinical management and to the limit inappropriate use of antibiotics.

Introduction

Fever is the one of the most common reasons that children present to Emergency departments in hospitals, especially in children under 5 years of age, in England [1] and in the US [2]. Serious bacterial infection accounts for 5-15% of the febrile children presenting [3][4][5] and most cases originating from a viral aetiology are self-limiting. Currently bacterial infection is confirmed by positive microbiological culture of a sterile sample (blood, clean catch urine or cerebrospinal fluids (CSF)). However, this can take 24-48 hours and is compounded by having a high false-negative [4,6] and false positive [7] rates by contaminating pathogens. Molecular detection of specific pathogens is an option but results can be confounded by co-infections and samples need to be obtained from the site of infection which can be both invasive and impractical [8]. Because it is challenging for paediatricians to differentiate between bacterial and viral infection in acute illness, antibiotics are often prescribed as a precautionary measure, contributing to the rise of antimicrobial resistance.

It is clear that reliable biomarkers are urgently needed that distinguish bacterial from viral infection for the purpose of good clinical management and reducing antibiotic use. Host biomarkers, i.e. the physiological changes of the host in response to a specific pathogen, have untapped diagnostic potential and their discovery can be accelerated by the advances in 'omics' research, especially in the field of transcriptomics [9–12] and proteomics [13–15]. Metabolomics has the added advantage that it is considered to most closely reflect the native phenotype and functional state of a biological system. One *In vivo* animal study revealed that distinct metabolic profiles can be derived from mice infected with different bacteria [16] and several similar studies focusing on meningitis have shown that metabolic profiling of CSF can differentiate between meningitis and negative controls [17], as well as between viral and bacterial meningitis [18]. Mason *et al* [19] demonstrated the possibility of diagnosis and prognosis of tuberculous meningitis with non-invasive urinary metabolic profiles. Metabolic changes in urine can be used to differentiate children with respiratory

syncytial virus (RSV) from healthy control, as well as from those with bacterial causes of respiratory distress [20].

Lipids are essential structural components of cell membranes and energy storage molecules. Thanks to the advances in lipidomics, a subset of metabolomics, lipids and lipid mediators have been increasingly recognised to play a crucial role in different metabolic pathways and cellular functions, particularly in immunity and inflammation [21,22]. However, the potential of lipidomics to distinguish bacterial from viral infection in febrile children has never been explored.

In this study, we undertook a lipidomic analysis of plasma taken from febrile children with confirmed bacterial infection (n=20) and confirmed viral infection (n=20) as a proof of concept study. We show that bacterial and viral infection elicit distinct changes in the plasma lipids of febrile children that might be exploited diagnostically.

Methods

Study population and sampling

The European Union Childhood Life-Threatening Infectious Disease Study (EUCLIDS) [23] prospectively recruited patients, aged from 1 month to 18 years, with sepsis or severe focal infection from 98 participating hospitals in the UK, Austria, Germany, Lithuania, Spain and the Netherlands between 2012 and 2015. Plasma and other biosamples were collected to investigate the underlying genetics, proteomics and metabolomics of children with severe infectious disease phenotype.

Infections in Children in the Emergency Department (ICED) study aimed to define clinical features that would predict bacterial illness in children and patterns of proteomics, genomics and metabolomics associated with infections. This study included children aged 0 -16 years at Imperial College NHS Healthcare Trust, St Mary's Hospital, between June 2014 and March 2015 [24].

The population consisted of children (≤ 17 years old) presenting with fever $\geq 38^\circ\text{C}$, with diverse clinical symptoms and a spectrum of pathogens. Both studies were approved by the local institutional review boards (ICED REC No 14/LO/0266; EUCLIDS REC No 11/LO/1982). Written informed consent was obtained from parents and assent from children, where appropriate. For the EUCLIDS study, a common clinical protocol agreed by EUCLIDS Clinical Network and approved by the Ethics Committee was implemented at all hospitals. Patients were divided into those with confirmed bacterial ($n=20$) and confirmed viral ($n=20$) infection groups. The bacterial group consisted exclusively of patients with confirmed sterile site culture-positive bacterial infections, and the viral infection group consisted of only patients with culture, molecular or immunofluorescent-confirmed viral infection and having no co-existing bacterial infection.

Blood samples were collected in tubes spray-coated with EDTA at, or as close as possible to, the time of presentation to hospital and plasma obtained by centrifugation of blood samples for 10 mins at 1,300 g at 4°C . Plasma was stored at -80°C before being shipped on dry ice to Imperial College London for lipidomic analysis.

Lipidomic analysis

Lipidomic analysis was carried out as previously described [25]. Briefly, 50 μl of water were added to 50 μl of plasma, vortexed and shaken for 5 min at 1,400 rpm at 4°C . Four hundred μl of isopropanol containing internal standards (9 in negative mode, 11 for positive mode covering 10 lipid sub-classes) were added for lipid extraction. Samples were shaken at 1,400 rpm for 2 hours at 4°C then centrifuged at 3,800 g for 10 min. Two aliquots of 100 μl of the supernatant fluid were transferred to a 96-well plate for ultra-performance liquid chromatography (UPLC) –mass spectrometry (MS) lipidomics analysis in positive and negative mode.

Liquid chromatography separation was carried out using an Acquity UPLC system (Waters Corporation, USA) with an injection volume of 1 μl and 2 μl for Positive and Negative ESI,

respectively. An Acquity UPLC BEH column (C8, 2.1 x 100 mm, 1.7 μ m; Waters Corporation, USA) was used for the purpose. Mobile phase A consisted of water/isopropanol/acetonitrile (2:1:1; v:v:v) with the addition of 5 mM ammonium acetate, 0.05% acetic acid and 20 μ M phosphoric acid. Mobile phase B consisted of isopropanol: acetonitrile (1:1; v:v) with the addition of 5mM ammonium acetate and 0.05% acetic acid. Flow rate was 0.6 ml/min with a total run time of 15 min and the gradient set as starting condition of 1% mobile phase B for 0.1 min, followed by an increase to 30% mobile phase B from 0.1 to 2 min, and to 90% mobile phase B from 2 min to 11.5 min. The gradient was held at 99.99% mobile phase B between 12 and 12.55 min before returning to the initial condition for re-equilibrium.

MS detection was achieved using a Xevo G2-S QToF mass spectrometer (Waters MS Technologies, UK) and data acquired in both positive and negative modes. The MS setting was configured as follows: capillary voltage 2.0 kV for Positive mode, 1.5 kV for Negative mode, sample cone voltage 25V, source offset 80, source temperature 120 $^{\circ}$ C, desolvation temperature 600 $^{\circ}$ C, desolvation gas flow 1000 L/h, and cone gas flow 150 L/h. Data were collected in centroid mode with a scan range of 50 -2000 m/z and a scan time of 0.1s. LockSpray mass correction was applied for mass accuracy using a 600 pg/ μ L leucine enkephaline (m/z 556.2771 in ESI+, m/z 554.2615 in ESI-) solution in water/acetonitrile solution (1:1; v/v) at a flow rate of 15 μ L/min.

Spectral and statistical analysis

A Study Quality Control sample (SQC) was prepared by pooling 25 μ L of all samples. The SQC was diluted to seven different concentrations, extracted at the same ratio 1:4 with isopropanol and replicates acquired at each concentration at the beginning and end of the run. A Long-Term Reference sample (LTR, made up of pooled plasma samples from external sources) and the SQC were diluted with water (1:1; v:v) and 400 μ L of isopropanol containing internal standards (the same preparation as for the study samples) and injected once every 10 study samples, with 5 samples between a LTR and a SQC. Deconvolution of

the spectra was carried out using the XCMS package. Extracted metabolic features were subsequently filtered and only those present with a relative coefficient of variation less than 15% across all SQC samples were retained. Additionally, metabolic features that did not correlate with a coefficient greater than 0.9 in a serial dilution series of SQC samples were removed.

Multivariate data analysis was carried out using SIMCA-P 14.1 (Umetrics AB, Sweden). The dataset was pareto-scaled prior to principal component analysis (PCA) and orthogonal partial least squares discriminate analysis (OPLS-DA). While PCA is an unsupervised technique useful for observing inherent clustering and identifying potential outliers in the dataset, OPLS-DA is a supervised method in which data is modelled against a specific descriptor of interest (in this case viral vs. bacterial infection classes). As for all supervised methods, model validity and robustness must be assessed before results can be interpreted. For OPLS-DA, model quality was assessed by internal cross-validation (Q^2Y -hat value) and permutation testing in which the true Q^2Y -hat value is compared to 999 models with random permutations of class membership. For valid and robust models (positive Q^2Y -hat and permutation p-value < 0.05), metabolic features responsible for class separation were identified by examining the corresponding S-plot (a scatter plot of model loadings and correlation to class) with a cut-off of 0.05.

Metabolite annotation

Short-listed metabolic features were subjected to tandem mass spectrometry in order to obtain fragmentation patterns. Patterns were compared against metabolome databases (Lipidmaps, HMDB, Metlin). Isotopic distribution matching was also checked. In addition, when possible the fragmented patterns were matched against available authentic standards run under the same analytical setting for retention time and MS/MS patterns. Annotation level, according to the Metabolomics Standards Initiative, are summarised in Table 2 [26].

Single feature ROC curve analysis

Analysis was performed with the web server, MetaboAnalyst 4.0. Sensitivities and specificities of lipids and predicted probabilities for the correct classification were presented as Receiver Operating Characteristic (ROC) curves. The Area Under the Curve (AUC) represents the discriminatory power of the lipids, with the value closest to 1 indicating the better classification.

Feature Selection

In order to identify a small diagnostic signature capable of differentiating between viral and bacterial infections, an 'in-house' variable selection method, forward selection-partial least squares (FS-PLS; <https://github.com/lachlancoin/fspls.git>), was used that eliminates highly correlated features. The first iteration of FS-PLS considers the levels of all features (N) and initially fits N univariate regression models. The regression coefficient for each model is estimated using the Maximum Likelihood Estimation (MLE) function, and the goodness of fit is assessed by a t-test. The variable with the highest MLE and smallest p-value is selected first (SV1). Before selecting which of the N-1 remaining variables to use next, the algorithm projects the variation explained by SV1 using Singular Value Decomposition. The algorithm iteratively fits up to N-1 models, at each step projecting the variation corresponding to the already selected variables, and selecting new variables based on the residual variation. This process terminates when the MLE p-value exceeds a pre-defined threshold (p_{thresh}). The final model includes regression coefficients for all selected variables. The sensitivity and specificity of the lipid signature identified by FS-PLS were presented as a receiver operating characteristic (ROC) curve.

Results

Patient characteristics

The baseline characteristics were divided into those with definitive bacterial and definitive viral infection, summarised in Table 1. When selecting patient samples, patient characteristics were matched as much as possible to ensure no particular factor would

confound the model. There was no significant difference in ages between the two groups ($p=0.97$). Both groups had similar gender split. Seven from definitive bacterial infection group and 6 from the definitive viral infection group were admitted to the Paediatric Intensive Care Unit (PICU). A range of pathogens was present in each group.

Plasma Lipidome can differentiate bacterial from viral infection

PCA was conducted first to evaluate the data, visualise dominant patterns, and identify outliers within populations (Figure 1). The same outlier sample was present in both negative (Figure 1A) and positive (Figure 1B) polarity datasets and as such, was removed from subsequent analysis. SQC samples were tightly grouped together in the PCA scatter plot, indicating minimum analytical variability throughout the run.

OPLS-DA, a supervised PCA method, was carried out on both positive and negative polarity datasets. In the positive polarity mode no model was successfully built to distinguish between viral and bacterial infection groups (data not shown). However, in the negative polarity dataset, an OPLS-DA model separated bacterial infected samples from viral infected samples. The robustness of the model was characterised by R^2X (cum) = 0.565, R^2Y -hat (cum)= 0.843 and Q^2Y -hat (cum)= 0.412 and permutation p -value=0.01 (999 tests). Cross-validated scores plot using the whole lipidome dataset indicated bacterial infected samples were more prone to miss-classification than viral infected samples (Figure 2A).

Lipid changes were not the same in the bacterial and viral infected groups

Metabolic features contributing to the separation of the model are plotted in Figure 2B and summarised in Table 2. Glycerophosphoinositol, monoacylglycerophosphocholine, sphingomyelin and sulfatide were only increased in the viral group, while fatty acids, glycerophosphocholine, glycerophosphoserine and lactosylceramide were only increased in bacterial infection. Bilirubin and cholesterol sulfate, although not lipids, were detected by lipidomic analysis, and these were increased in the bacterial and viral groups, respectively.

Evaluation of diagnostic potential of metabolic biomarkers

ROC curve analysis was performed to evaluate the diagnostic potential of these lipids in distinguishing bacterial from viral infection. Out of all discriminatory lipids, PC (16:0/16:0), unknown feature m/z 239.157 and PE (16:0/18:2) generated the highest AUCs of 0.774 (CI, 0.6-0.902), 0.721 (CI, 0.545- 0.871) and 0.705 (CI, 0.52 – 0.849), respectively (Figure 3).

FS-PLS was used to identify a small signature composed of non-correlated lipids that is capable of distinguishing between bacterial and viral samples. FS-PLS identified a signature made up the following 3 lipids: SHexCer(d42:3); PC (16:0/16:0); and LacCer(d18:1/24:1). This signature achieved an improved ROC curve with AUC of 0.9158 (95% confidence interval: 0.828 – 1) when compared with those generated from individual lipids (Figure 4).

Discussion

We have shown that differences in the host lipidome are induced by bacterial and viral infections. While differences in host responses between viral and bacterial infections have been previously reported, for example as differential expression of proteins, RNAs and level of metabolites [9–14,20], there have been no claims in relation to the lipidome changes in carefully-phenotyped samples. Although age is known to affect metabolism [27], it is important to note the metabolic changes associated with infection described herein, were consistent among samples from patients whose age ranged from 1 month to 9 years old.

Glycerophosphoinositol, sphingomyelin, lysophosphatidylcholine and cholesterol sulfate were increased in the confirmed virus-infected group, while fatty acids, glycerophosphocholine, glycerophosphoserine, lactosylceramide and bilirubin were increased in cases with confirmed bacterial infection.

The important effects of infection on fatty acid metabolism have been highlighted by Munger *et al* who demonstrated human cytomegalovirus (HCMV) up-regulated fatty acid biosynthesis in infected host cells. Pharmacologically inhibition of fatty acid biosynthesis suppressed viral replication for both HCMV and influenza A virus [28]. The importance of fatty acid biosynthesis may reflect its essential role in viral envelopment during viral replication. Rhinovirus induced metabolic reprogramming in host cell by increasing glucose uptake and indicated a shift towards lipogenesis and/or fatty acid uptake [29]. In our study, fatty acids linoleic acid (FA 18:2), palmitic acid (FA 16:0), oleic acid (FA 18:1) and palmitoleic acid (FA 16:1) were all decreased in viral infection (i.e. increased in bacterial infection), and may reflect enhanced lipogenesis and fatty acid uptake in the host cell during viral replication.

The increase in cholesterol sulfate observed may reflect changes in cellular lipid biosynthesis and T cell signalling during viral infection. Cholesterol sulfate is believed to play a key role as a membrane stabiliser [30] and can also act to modulate cellular lipid

biosynthesis [31] and T cell receptor signal transduction [32]. Gong *et al* demonstrated that cholesterol sulfate was elevated in the serum of piglets infected with swine fever virus [33]. Taken together, these observations indicate that this compound could be a marker of viral infection.

The increase in sphingomyelin SM(d18:1/24:1), SM(d18:1/23:0) and SM(d18:1/24:0), and lysophosphocholine LPC (16:0) upon viral infection may also be linked to viral replication in infected cells. Accumulation of cone-shaped lipids, such as LPC in one leaflet of the membrane bilayer induces membrane curvature required for virus budding [34]. It is known that viral replication, for example in the case of dengue virus, induces dramatic changes in infected cells, including sphingomyelin, to alter the curvature and permeability of membranes [35]. Furthermore, the altered levels of sphingomyelin can be partially explained by elevated cytokine levels during bacterial infection, such as TNF- α [36], which can activate sphingomyelinase, hydrolysing sphingomyelin to ceramide [37]. Hence, sphingomyelin may be a class of lipids that plays a role in both viral and bacterial infection.

Lactosylceramide LacCer(d18:1/24:1) and LacCer (d18:1/16:0) were increased in bacterial infection. Lactosylceramide, found in microdomains on the plasma membrane of cells, is a glycosphingolipid consisting of a hydrophobic ceramide lipid and a hydrophilic sugar moiety. Lactosylceramide plays an important role in bacterial infection by serving as a pattern recognition receptors (PRRs) to detect pathogen-associated molecular patterns (PAMPs). Lactosylceramide composed of long chain fatty acid chain C24, such as LacCer(d:18:1/24:1) increased in our study, is essential for formation of LacCer-Lyn complexes on neutrophils, which function as signal transduction platforms for $\alpha M\beta 2$ integrin-mediated phagocytosis [38].

Other lipids that were changed in our study, such as sulfatides and glycerophosphocolines, may also play an important role in bacterial infection. Sulfatides are multifunctional molecules involved in various biological process, including immune system regulation and during infection [39]. Sulfatides can act as glycolipid receptors that attach bacteria, such as

Escherichia coli [40], *Mycoplasma hyopneumoniae* [41] and *Pseudomonas aeruginosa* [42] to the mucosal surfaces. Five glycerophosphocholine species including PC(16:0/18:2), PC(18:0/18:1), PC(18:0/18:2), PC(16:0/16:0) and PC(16:0/18:1) were increased in bacterial infected samples. The increase in glycerophosphocholine was demonstrated in a lipidomics study looking at plasma from tuberculosis patients [43], however, the exact role of glycerophosphocholine remains elusive. Bilirubin is detected as a consequence of breadth of lipidome coverage, and its role in infection is unclear. The lipid species identified in this study present an opportunity for further mechanistic study to understand the host responses in bacterial or viral infection.

A combination of three lipids achieved a strong area under the receiver operating characteristic (ROC) curve of 0.918 (95% CI 0.835 to 1). Similar approaches have been taken using routine laboratory parameters and more recently gene expression where 2-gene transcripts achieved an ROC curve of 0.95 (95% CI 0.94 -1) [11]. The relevance of our data is that they provide the potential for a rapid diagnostic test with which clinicians could distinguish bacterial from viral infection in febrile children.

The study has limitations. Firstly, we were unable to annotate 4 of the 29 discriminatory features, of which two were assigned with only a broad lipid class by identifying the head group (PE). The unknown feature with m/z of 239.157 achieved the second highest AUC for ROC curve analysis on an individual basis. The unknown identity prevents this feature from being a potential marker and hinders biological understanding. This feature, however, was not included in the final 3-lipid panel that gave the highest AUC. Secondly, the sample size in this pilot study is small. Validation studies using quantitative assay are now required to confirm the findings.

This is the first lipidomics study carried out on plasma taken from febrile children for the purpose of distinguishing bacterial from viral infection. It demonstrates the potential of this approach to facilitate effective clinical management by rapidly diagnosing bacterial infection in paediatrics.

References

1. Hay AD, Heron J, Ness A. The prevalence of symptoms and consultations in pre-school children in the Avon Longitudinal Study of Parents and Children (ALSPAC): a prospective cohort study. *Fam Pract* [Internet]. Oxford University Press; **2005** [cited 2018 Mar 12]; 22(4):367–374. Available from: <http://academic.oup.com/fampra/article/22/4/367/662712/The-prevalence-of-symptoms-and-consultations-in>
2. Alpern ER, Stanley RM, Gorelick MH, et al. Epidemiology of a Pediatric Emergency Medicine Research Network. *Pediatr Emerg Care* [Internet]. **2006** [cited 2019 Mar 12]; 22(10):689–699. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/17047467>
3. Hsiao AL, Chen L, Baker MD, et al. Incidence and predictors of serious bacterial infections among 57- to 180-day-old infants. *Pediatrics* [Internet]. American Academy of Pediatrics; **2006** [cited 2018 Jul 16]; 117(5):1695–701. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/8065869>
4. Craig JC, Williams GJ, Jones M, et al. The accuracy of clinical symptoms and signs for the diagnosis of serious bacterial infection in young febrile children: prospective cohort study of 15 781 febrile illnesses. *BMJ* [Internet]. British Medical Journal Publishing Group; **2010** [cited 2018 Mar 5]; 340:c1594. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/20406860>
5. Nijman RG, Vergouwe Y, Thompson M, et al. Clinical prediction model to aid emergency doctors managing febrile children at risk of serious bacterial infections: diagnostic study. *BMJ* [Internet]. British Medical Journal Publishing Group; **2013** [cited 2018 Mar 8]; 346:f1706. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/23550046>
6. Doare K Le, Nichols A-L, Payne H, et al. Very low rates of culture-confirmed invasive bacterial infections in a prospective 3-year population-based surveillance in

- Southwest London. Arch Dis Child [Internet]. BMJ Publishing Group Ltd; **2014** [cited 2018 Mar 5]; 99(6):526–31. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/24554055>
7. Hall KK, Lyman JA. Updated review of blood culture contamination. Clin Microbiol Rev [Internet]. American Society for Microbiology (ASM); **2006** [cited 2019 May 18]; 19(4):788–802. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/17041144>
8. Gill PJ, Richardson SE, Ostrow O, Friedman JN. Testing for Respiratory Viruses in Children. JAMA Pediatr [Internet]. **2017** [cited 2018 Jul 16]; 171(8):798. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/28672402>
9. Ramilo O, Mejías A. Shifting the Paradigm: Host Gene Signatures for Diagnosis of Infectious Diseases. Cell Host Microbe [Internet]. Cell Press; **2009** [cited 2018 Jul 16]; 6(3):199–200. Available from: <https://www.sciencedirect.com/science/article/pii/S1931312809002868?via%3Dihub>
10. Tsalik EL, Henao R, Nichols M, et al. Host gene expression classifiers diagnose acute respiratory illness etiology. Sci Transl Med [Internet]. **2016** [cited 2018 Apr 30]; 8(322):322ra11-322ra11. Available from: <http://stm.sciencemag.org/lookup/doi/10.1126/scitranslmed.aad6873>
11. Herberg JA, Kaforou M, Wright VJ, et al. Diagnostic Test Accuracy of a 2-Transcript Host RNA Signature for Discriminating Bacterial vs Viral Infection in Febrile Children. JAMA [Internet]. American Medical Association; **2016** [cited 2018 Mar 5]; 316(8):835. Available from: <http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2016.11236>
12. Mahajan P, Kuppermann N, Mejias A, et al. Association of RNA Biosignatures With Bacterial Infections in Febrile Infants Aged 60 Days or Younger. JAMA [Internet]. American Medical Association; **2016** [cited 2018 Jul 16]; 316(8):846. Available from: <http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2016.9207>

13. Oved K, Cohen A, Boico O, et al. A Novel Host-Proteome Signature for Distinguishing between Acute Bacterial and Viral Infections. Schildgen O, editor. PLoS One [Internet]. Public Library of Science; **2015** [cited 2018 Mar 5]; 10(3):e0120012. Available from: <http://dx.plos.org/10.1371/journal.pone.0120012>
14. Eden E, Srugo I, Gottlieb T, et al. Diagnostic accuracy of a TRAIL, IP-10 and CRP combination for discriminating bacterial and viral etiologies at the Emergency Department. J Infect [Internet]. **2016** [cited 2018 Jul 16]; 73(2):177–180. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/27255416>
15. Ashkenazi-Hoffnung L, Oved K, Navon R, et al. A host-protein signature is superior to other biomarkers for differentiating between bacterial and viral disease in patients with respiratory infection and fever without source: a prospective observational study. Eur J Clin Microbiol Infect Dis [Internet]. **2018** [cited 2018 Jul 16]; 37(7):1361–1371. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/29700762>
16. Hoerr V, Zbytnuik L, Leger C, Tam PPC, Kubes P, Vogel HJ. Gram-negative and Gram-Positive Bacterial Infections Give Rise to a Different Metabolic Response in a Mouse Model. J Proteome Res [Internet]. American Chemical Society; **2012** [cited 2018 Mar 5]; 11(6):3231–3245. Available from: <http://pubs.acs.org/doi/10.1021/pr201274r>
17. Chatterji T, Singh S, Sen M, et al. Proton NMR metabolic profiling of CSF reveals distinct differentiation of meningitis from negative controls. Clin Chim Acta [Internet]. Elsevier; **2017** [cited 2018 Mar 5]; 469:42–52. Available from: <https://www.sciencedirect.com/science/article/pii/S0009898117300906>
18. Coen M, O’Sullivan M, Bubb WA, Kuchel PW, Sorrell T. Proton nuclear magnetic resonance-based metabonomics for rapid diagnosis of meningitis and ventriculitis. Clin Infect Dis [Internet]. **2005** [cited 2018 Mar 5]; 41(11):1582–90. Available from: <https://watermark.silverchair.com/41-11->

1582.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAA
Ab8wggG7BqkqhkiG9w0BBwagggGsMIIBqAIBADCCAaEGCSqGSib3DQEHATAeBgl
ghkgBZQMEAS4wEQQMj50zgVd9IArTF0bvAgEQglBckjIWKRLYYaCTDrIXEOip8ivS
B1XYP81HhjXX6857XAU

19. Mason S, Furth AMT van, Solomons R, Wevers RA, Reenen M van, Reinecke CJ. A putative urinary biosignature for diagnosis and follow-up of tuberculous meningitis in children: outcome of a metabolomics study disclosing host–pathogen responses. *Metabolomics* [Internet]. Springer US; **2016** [cited 2018 Jul 16]; 12(7):110. Available from: <http://link.springer.com/10.1007/s11306-016-1053-2>
20. Adamko DJ, Saude E, Bear M, Regush S, Robinson JL. Urine metabolomic profiling of children with respiratory tract infections in the emergency department: a pilot study. *BMC Infect Dis* [Internet]. BioMed Central; **2016** [cited 2018 Jul 10]; 16(1):439. Available from: <http://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-016-1709-6>
21. Arita M. Mediator lipidomics in acute inflammation and resolution. *J Biochem* [Internet]. Narnia; **2012** [cited 2019 Apr 19]; 152(4):313–319. Available from: <https://academic.oup.com/jb/article-lookup/doi/10.1093/jb/mvs092>
22. Zhang C, Wang K, Yang L, et al. Lipid metabolism in inflammation-related diseases. *Analyst* [Internet]. The Royal Society of Chemistry; **2018** [cited 2019 Apr 19]; 143(19):4526–4536. Available from: <http://xlink.rsc.org/?DOI=C8AN01046C>
23. Martín-Torres F, Salas A, Rivero-Calle I, et al. Life-threatening infections in children in Europe (the EUCLIDS Project): a prospective cohort study. *Lancet Child Adolesc Heal* [Internet]. Elsevier; **2018** [cited 2018 Nov 4]; 2(6):404–414. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/30169282>
24. Levin M, Cunnington AJ, Wilson C, et al. Adverse effects of saline or albumin fluid bolus in resuscitation: evidence from the FEAST Trial, *Lancet Resp Med*, accepted.

25. Izzi-Engbeaya C, Comninou AN, Clarke SA, et al. The effects of kisspeptin on β -cell function, serum metabolites and appetite in humans. *Diabetes, Obes Metab* [Internet]. John Wiley & Sons, Ltd (10.1111); **2018** [cited 2019 Mar 13]; 20(12):2800–2810. Available from: <http://doi.wiley.com/10.1111/dom.13460>
26. Sumner LW, Amberg A, Barrett D, et al. Proposed minimum reporting standards for chemical analysis Chemical Analysis Working Group (CAWG) Metabolomics Standards Initiative (MSI). *Metabolomics* [Internet]. NIH Public Access; **2007** [cited 2019 Mar 12]; 3(3):211–221. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/24039616>
27. Hines RN. The ontogeny of drug metabolism enzymes and implications for adverse drug events. **2008** [cited 2019 Feb 27]; . Available from: <http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.568.6447&rep=rep1&type=pdf>
28. Munger J, Bennett BD, Parikh A, et al. Systems-level metabolic flux profiling identifies fatty acid synthesis as a target for antiviral therapy. *Nat Biotechnol* Vol [Internet]. **2008** [cited 2019 Feb 12]; 26. Available from: <http://www.nature.com/naturebiotechnology>
29. Designed Research; G JSAG. Rhinovirus induces an anabolic reprogramming in host cell metabolism essential for viral replication used new reagents/analytic tools; G. **2018** [cited 2019 Feb 12]; . Available from: <https://www.pnas.org/content/pnas/115/30/E7158.full.pdf>
30. Strott CA, Higashi Y. Cholesterol sulfate in human physiology: what's it all about? *J Lipid Res* [Internet]. **2003** [cited 2019 Mar 13]; 44. Available from: <http://www.jlr.org>
31. Festa A, Williams K, Hanley AJG, et al. Nuclear magnetic resonance lipoprotein abnormalities in prediabetic subjects in the Insulin Resistance Atherosclerosis Study. *Circulation* [Internet]. Department of Medicine, University of Texas Health Science Center, San Antonio, TX 78229-3900, USA.; **2005**; 111(25):3465–3472. Available

from: papers2://publication/doi/10.1161/CIRCULATIONAHA.104.512079

32. Wang F, Beck-García K, Zorzín C, Schamel WWA, Davis MM. Inhibition of T cell receptor signaling by cholesterol sulfate, a naturally occurring derivative of membrane cholesterol. *Nat Immunol* [Internet]. Nature Publishing Group; **2016** [cited 2019 Mar 13]; 17(7):844–850. Available from: <http://www.nature.com/articles/ni.3462>
33. Gong W, Jia J, Zhang B, et al. Serum Metabolomic Profiling of Piglets Infected with Virulent Classical Swine Fever Virus. *Front Microbiol* [Internet]. **2017** [cited 2019 Mar 13]; 8:731. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/28496435>
34. Heaton NS, Randall G. Multifaceted roles for lipids in viral infection. *Trends Microbiol* [Internet]. Elsevier Current Trends; **2011** [cited 2019 May 18]; 19(7):368–375. Available from: <https://www.sciencedirect.com/science/article/pii/S0966842X11000576?via%3Dihub#bib0175>
35. Perera MN, Ganesan V, Siskind LJ, et al. Ceramide channels: influence of molecular structure on channel formation in membranes. *Biochim Biophys Acta* [Internet]. NIH Public Access; **2012** [cited 2019 Feb 6]; 1818(5):1291–301. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/22365970>
36. Holub M, Lawrence DA, Andersen N, et al. Cytokines and chemokines as biomarkers of community-acquired bacterial infection. *Mediators Inflamm* [Internet]. Hindawi; **2013** [cited 2019 Feb 20]; 2013:190145. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/23690657>
37. Maceyka M, Spiegel S. Sphingolipid metabolites in inflammatory disease. *Nature* [Internet]. Nature Publishing Group; **2014** [cited 2019 Feb 20]; 510(7503):58–67. Available from: <http://www.nature.com/articles/nature13475>
38. Ekyalongo RC, Nakayama H, Kina K, Kaga N, Iwabuchi K. Organization and functions

of glycolipid-enriched microdomains in phagocytes. *Biochim Biophys Acta - Mol Cell Biol Lipids* [Internet]. Elsevier; **2015** [cited 2019 Feb 20]; 1851(1):90–97. Available from: <https://www.sciencedirect.com/science/article/pii/S1388198114001206>

39. Takahashi T, Suzuki T. Role of sulfatide in normal and pathological cells and tissues. *J Lipid Res* [Internet]. American Society for Biochemistry and Molecular Biology; **2012** [cited 2019 May 18]; 53(8):1437–50. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/22619219>

40. Jansson L, Tobias J, Jarefjäll C, Lebens M, Svennerholm A-M, Teneberg S. Sulfatide Recognition by Colonization Factor Antigen CS6 from Enterotoxigenic *Escherichia coli*. Horsburgh MJ, editor. *PLoS One* [Internet]. **2009** [cited 2019 May 18]; 4(2):e4487. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/19242561>

41. Zhang Q, Young TF, Ross RF. Glycolipid receptors for attachment of *Mycoplasma hyopneumoniae* to porcine respiratory ciliated cells. *Infect Immun* [Internet]. American Society for Microbiology (ASM); **1994** [cited 2019 May 18]; 62(10):4367–73. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/7927697>

42. Yagci A, Sener B, Suziki Y, Ahmed K. Sulfatide mediates attachment of *Pseudomonas aeruginosa* to human pharyngeal epithelial cells [Internet]. *New Microbiol*. 2007. Available from: http://www.newmicrobiologica.org/PUB/allegati_pdf/2007/2/15_YAGCI.pdf

43. Wood PL, Tippireddy S, Feriante J. Plasma lipidomics of tuberculosis patients: altered phosphatidylcholine remodeling. *Futur Sci OA* [Internet]. Future Science Ltd London, UK ; **2018** [cited 2019 May 18]; 4(1):FSO255. Available from: <http://www.future-science.com/doi/10.4155/fsoa-2017-0011>

Table 1 Demographic and clinical patient characteristic

Patients with confirmed	Bacterial infection (N=20)	Viral infection (N=20)	P value
Age, median (range), month	9 (1-102)	8 (1-93)	p=0.48
Male, No. (%)	11 (55)	10 (50)	-
White race, No./total (%)	14/19 (74)	11/20 (55)	-
Time from symptoms to blood sampling, median (range), day	2 (0-9)	3 (0-15)	p=0.16
Intensive care, No. (%)	7 (35)	6 (30)	-
Fatalities, No.	1	0	-
Pathogen* (#cases)	Coliform (1) <i>B. pertussis</i> (2) <i>E.coli</i> (2) <i>S. Pneumoniae</i> (3) <i>S. aureus</i> (1) <i>E. cloacae</i> (1) <i>N. Meningitidis</i> (8) <i>K. Kingae</i> (1) <i>Klebsiella oxytoca</i> (1) <i>Group A streptococcus</i> (1)**	Enterovirus (3) Influenza A (2) Parechovirus (1) Respiratory syncytial virus (5) Rhinovirus (3) Adenovirus (4) Human Metapneumovirus (1) Parainfluenza virus (1) Human herpesvirus 6 (1) Herpes simplex virus (1) Rotavirus (1)	

* Some patients are co-infected with more than one pathogen

** The patient with *Group A streptococcus* was excluded from the subsequent data analysis as being an outlier.

Figure 1. Principal components analysis (PCA) of lipidomics dataset. (A) Scatter plot of PCA model from data acquired in negative polarity mode. (B) Scatter plot of PCA model from data acquired in positive polarity mode. Quality control samples are shown in red, bacterial infected samples are shown in blue and viral infected samples shown in green.

Table 2. Metabolic features changed in bacterial and viral group.

	m/z	retention time	annotation	annotation level	ion type	neutral formula
Lipids/metabolites increased in bacterial infected group	279.231	2.52	FA(18:2)	2	[M-H]-	C18H32O2
	255.232	2.82	FA(16:0)	2	[M-H]-	C16H32O2
	281.247	2.96	FA(18:1)	2	[M-H]-	C18H34O2
	788.545	6.22	PS(18:0/18:1)	2	[M-H]-	C39H74NO8P
	253.216	2.35	FA(16:1)	2	[M-H]-	C16H30O2
	742.54	6.06	PC(16:0/18:2)	2	[M-CH3]-	C42H80NO8P
	716.524	6.75	PE(16:0/18:1)	2	[M-H]-	C39H76NO8P
	583.256	1.18	Bilirubin	2	[M-H]-	C33H36N4O6
	810.53	5.76	PS(18:0/20:4)	2	[M-H]-	C44H78NO10P
	846.624	7.23	PC(18:0/18:1)	2	[M+PO4H2]-	C44H86NO8P
	1068.7	7.80	LacCer(d18:1/24:1)	2	[M+PO4H2]-	C54H101NO13
	770.571	6.78	PC(18:0/18:2)	2	[M-CH3]-	C44H84NO8P
	744.556	6.60	PC(16:0/18:1)	2	[M-CH3]-	C42H82NO8P
	958.589	5.78	LacCer(d18:1/16:0)	2	[M+PO4H2]-	C46H87NO13
	718.54	6.41	PC(16:0/16:0)	2	[M-CH3]-	C40H80NO8P
	742.54	6.90	PE(18:0/18:2)	2	[M-H]-	C41H78NO8P
Lipids/metabolites increased in viral infected group	465.303	2.55	Cholesterol sulfate	2	[M-H]-	C27H46O4S
	465.303	2.61	Cholesterol sulfate	2	[M-H]-	C27H46O4S
	909.551	5.56	PI(18:0/22:6)	2	[M-H]-	C49H83O13P
	861.55	5.75	PI(18:0/18:2)	2	[M-H]-	C45H83O13P
	797.655	7.78	SM(d18:1/24:1)	2	[M-CH3]-	C47H93N2O6P
	339.231	2.66	UNKNOWN1	4		
	772.529	6.49	PE1	3	[M-H]-	C45H76NO7P
	897.648	8.12	SM(d18:1/23:0)	2	[M+PO4H2]-	C46H93N2O6P
	239.157	0.87	UNKNOWN2	4		
	886.609	6.31	SHexCer(d42:3)	2	[M-H]-	C48H89NO11S
	554.346	1.86	LPC(16:0/0:0)	2	[M+CH3COO]-	C24H50NO7P
	799.671	8.41	SM(d18:1/24:0)	2	[M-CH3]-	C47H95N2O6P
	750.545	7.24	PE2	3	[M-H]-	C41H78NO7P

FA: fatty acid; PE: glycerophosphotidylethanolamine; PC: glycerophosphocholine; PS: glycerophosphoserine; LacCer: lactosylceramide; PI: glycerophosphoinositol; SM: sphingomyelin; LPC: Lysophosphotidylcholine; SHexCer: Sulfatides.

Figure 3. Receiver operator characteristic (ROC) analysis based on single lipids. ROC curve analysis of top 3 lipids PC (16:0/16:0) (A), unknown feature (m/z 239.157) (B) and PE (16:0/18:2) (C) which gave with highest Area Under the Curve (AUC) values.

Figure 4. Receiver operator characteristic (ROC) analysis based on 3-lipid signature. A
combination of SHexCer(d42:3), PC (16:0/16:0) and LacCer(d18:1/24:1) achieved AUC of
0.911 (CI 95% 0.821-1.000).

561 Appendix: EUCLIDS Consortium members

562 EUCLIDS consortium (www.euclids-project.eu) is composed by:

563 **Imperial College partner (UK)**

564 **Members of the EUCLIDS Consortium at Imperial College London (UK)** 565 **Principal and co-investigators** 566

567 Michael Levin (grant application, EUCLIDS Coordinator)

568 Lachlan Coin (bioinformatics)

569 Stuart Gormley (clinical coordination)

570 Shea Hamilton (proteomics)

571 Jethro Herberg (grant application, PI)

572 Bernardo Hourmat (project management)

573 Clive Hoggart (statistical genomics)

574 Myrsini Kaforou (bioinformatics)

575 Vanessa Sancho-Shimizu (genetics)

576 Victoria Wright (grant application, scientific coordination)

577 **Consortium members at Imperial College**

578 Amina Abdulla

579 Paul Agapow

580 Maeve Bartlett

581 Evangelos Bellos

582 Hariklia Eleftherohorinou

583 Rachel Galassini

584 David Inwald

585 Meg Mashbat

586 Stefanie Menikou

587 Sobia Mustafa

588 Simon Nadel

589 Rahmeen Rahman

590 Clare Thakker

591 **EUCLIDS UK Clinical Network**

- 592 Poole Hospital NHS Foundation Trust, Poole: Dr S Bokhandi (PI), Sue Power, Heather
593 Barham
- 594 Cambridge University Hospitals NHS Trust, Cambridge: Dr N Pathan (PI), Jenna Ridout,
595 Deborah White, Sarah Thurston
- 596 University Hospital Southampton, Southampton: Prof S Faust (PI), Dr S Patel
597 (coinvestigator), Jenni McCorkell.
- 598 Nottingham University Hospital NHS Trust: Dr P Davies (PI), Lindsey Crate, Helen Navarra,
599 Stephanie Carter 2
- 600 University Hospitals of Leicester NHS Trust, Leicester: Dr R Ramaiah (PI), Rekha Patel
- 601 Portsmouth Hospitals NHS Trust, London: Dr Catherine Tuffrey (PI), Andrew Gribbin,
602 Sharon McCready
- 603 Great Ormond Street Hospital, London: Dr Mark Peters (PI), Katie Hardy, Fran Standing,
604 Lauren O'Neill, Eugenia Abelake
- 605 King's College Hospital NHS Foundation Trust, London; Dr Akash Deep (PI), Eniola Nsirim
- 606 Oxford University Hospitals NHS Foundation Trust, Oxford Prof A Pollard (PI), Louise Willis,
607 Zoe Young
- 608 Kettering General Hospital NHS Foundation Trust, Kettering: Dr C Royad (PI), Sonia White
- 609 Central Manchester NHS Trust, Manchester: Dr PM Fortune (PI), Phil Hudnott
- 610 **SERGAS Partner (Spain)**
- 611 **Principal Investigators**
- 612 Federico Martínón-Torres¹
- 613 Antonio Salas^{1,2}
- 614 **GENVIP RESEARCH GROUP** (in alphabetical order):
- 615 Fernando Álvarez González¹, Ruth Barral-Arca^{1,2}, Miriam Cebey-López¹, María José
616 Curras-Tuala^{1,2}, Natalia García¹, Luisa García Vicente¹, Alberto Gómez-Carballa^{1,2}, Jose
617 Gómez Rial¹, Andrea Grela Beiroa¹, Antonio Justicia Grande¹, Pilar Leboráns Iglesias¹,
618 Alba Elena Martínez Santos¹, Federico Martínón-Torres¹, Nazareth MartínónTorres¹,
619 José María Martínón Sánchez¹, Beatriz Morillo Gutiérrez¹, Belén Mosquera Pérez¹, Pablo
620 Obando Pacheco¹, Jacobo Pardo-Seco^{1,2}, Sara Pischedda^{1,2}, Irene RiveroCalle¹,
621 Carmen Rodríguez-Tenreiro¹, Lorenzo Redondo-Collazo¹, Antonio Salas Ellacuriaga^{1,2},
622 Sonia Serén Fernández¹, María del Sol Porto Silva¹, Ana Vega^{1,3}, Lucía Vilanova Trillo¹.
- 623 ¹ Translational Pediatrics and Infectious Diseases, Pediatrics Department, Hospital Clínico
624 Universitario de Santiago, Santiago de Compostela, Spain, and GENVIP Research Group
625 (www.genvip.org), Instituto de Investigación Sanitaria de Santiago, Galicia, Spain.
- 626 ² Unidade de Xenética, Departamento de Anatomía Patolóxica e Ciencias Forenses,
627 Instituto de Ciencias Forenses, Facultade de Medicina, Universidade de Santiago de
628 Compostela, and GenPop Research Group, Instituto de Investigacións Sanitarias (IDIS),
629 Hospital Clínico Universitario de Santiago, Galicia, Spain
- 630 ³ Fundación Pública Galega de Medicina Xenómica, Servizo Galego de Saúde (SERGAS),
631 Instituto de Investigacións Sanitarias (IDIS), and Grupo de Medicina Xenómica, Centro de
632 Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Universidade de
633 Santiago de Compostela (USC), Santiago de Compostela, Spain

EUCLIDS SPANISH CLINICAL NETWORK:

Susana Beatriz Reyes¹ , María Cruz León León¹ , Álvaro Navarro Mingorance¹ , Xavier Gabaldó Barrios¹ , Eider Oñate Vergara² , Andrés Concha Torre³ , Ana Vivanco³ , Reyes Fernández³ , Francisco Giménez Sánchez⁴ , Miguel Sánchez Forte⁴ , Pablo Rojo⁵ , J.Ruiz Contreras⁵ , Alba Palacios⁵ , Cristina Epalza Ibarrondo⁵ , Elizabeth Fernández Cooke⁵ , Marisa Navarro⁶ , Cristina Álvarez Álvarez⁶ , María José Lozano⁶ , Eduardo Carreras⁷ , Sonia Brió Sanagustín⁷ , Olaf Neth⁸ , M^a del Carmen Martínez Padilla⁹ , Luis Manuel Prieto Tato¹⁰ , Sara Guillén¹⁰ , Laura Fernández Silveira¹¹ , David Moreno¹².

1 Hospital Clínico Universitario Virgen de la Arrixaca; Murcia, Spain.

2 Hospital de Donostia; San Sebastián, Spain.

3 Hospital Universitario Central de Asturias; Asturias, Spain.

4 Complejo Hospitalario Torrecárdenas; Almería, Spain.

5 Hospital Universitario 12 de Octubre; Madrid, Spain.

6 Hospital General Universitario Gregorio Marañón; Madrid, Spain.

7 Hospital de la Santa Creu i Sant Pau; Barcelona, Spain.

8 Hospital Universitario Virgen del Rocío; Sevilla, Spain.

9 Complejo Hospitalario de Jaén; Jaén, Spain.

10 Hospital Universitario de Getafe; Madrid, Spain.

11 Hospital Universitario y Politécnico de La Fe; Valencia, Spain.

12 Hospital Regional Universitario Carlos Haya; Málaga, Spain.

Members of the Pediatric Dutch Bacterial Infection Genetics (PeD-BIG) network (the Netherlands)

Steering committee:

Coordination: R. de Groot ¹ , A.M. Tutu van Furth ² , M. van der Flier ¹

Coordination Intensive Care: N.P. Boeddha ³ , G.J.A. Driessen ³ , M. Emonts ^{3, 4, 5} , J.A. Hazelzet ³

Other members: T.W. Kuijpers ⁷ , D. Pajkrt ⁷ , E.A.M. Sanders ⁶ , D. van de Beek ⁸ , A. van der Ende ⁸

Trial coordinator: H.L.A. Philipsen ¹

Local investigators (in alphabetical order)

A.O.A. Adeel ⁹ , M.A. Breukels ¹⁰ , D.M.C. Brinkman ¹¹ , C.C.M.M. de Korte ¹² , E. de Vries ¹³ , W.J. de Waal ¹⁵ , R. Dekkers ¹⁵ , A. Dings-Lammertink ¹⁶ , R.A. Doedens ¹⁷ , A.E. Donker ¹⁸ , M. Dousma¹⁹ , T.E. Faber ²⁰ , G.P.J.M. Gerrits²¹ , J.A.M. Gerver ²² , J. Heidema ²³ , J. Homan-van der Veen ²⁴ , M.A.M. Jacobs ²⁵ , N.J.G. Jansen ⁶ , P. Kawczynski ²⁶ , K. Klucovska ²⁷ , M.C.J. Kneyber ²⁸ , Y. Koopman-Keemink ²⁹ , V.J. Langenhorst ³⁰ , J. Leusink ³¹ , B.F. Loza ³² , I.T. Merth ³³ , C.J. Miedema ³⁴ , C. Neeleman ¹ , J.G. Noordzij ³⁵ , C.C. Obihara ³⁶ , A.L.T. van Overbeek – van Gils ³⁷ , G.H. Poortman ³⁸ , S.T. Potgieter ³⁹ , J. Potjewijd ⁴⁰ , P.P.R. Rosias ⁴¹ , T. Sprong ²¹ , G.W. ten Tusscher ⁴² , B.J. Thio ⁴³ , G.A. Tramper-Stranders ⁴⁴ , M. van Deuren ¹ , H. van der Meer ² , A.J.M. van Kuppevelt ⁴⁵ , A.M. van Wermeskerken ⁴⁶ , W.A. Verwijs ⁴⁷ , T.F.W. Wolfs ⁴ .

- 675 1. Radboud University Medical Center – Amalia Children’s Hospital, Nijmegen, The
676 Netherlands
- 677 2. Vrije Universiteit University Medical Center, Amsterdam, The Netherlands
- 678 3. Erasmus Medical Center – Sophia Children’s Hospital, Rotterdam, The Netherlands
- 679 4. Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United
680 Kingdom
- 681 5. Paediatric Infectious Diseases and Immunology Department, Newcastle upon Tyne
682 Hospitals Foundation Trust, Great North Children's Hospital, Newcastle upon Tyne, United
683 Kingdom
- 684 6. University Medical Center Utrecht – Wilhelmina Children’s Hospital, Utrecht, The
685 Netherlands
- 686 7. Academic Medical Center – Emma Children’s Hospital, University of Amsterdam,
687 Amsterdam, The Netherlands
- 688 8. Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
- 689 9. Kennemer Gasthuis, Haarlem, The Netherlands
- 690 10. Elkerliek Hospital, Helmond, The Netherlands
- 691 11. Alrijne Hospital, Leiderdorp, The Netherlands
- 692 2. Beatrix Hospital, Gorinchem, The Netherlands
- 693 13. Jeroen Bosch Hospital, ‘s-Hertogenbosch, The Netherlands
- 694 14. Diaconessenhuis, Utrecht, The Netherlands
- 695 15. Maasziekenhuis Pantein, Boxmeer, The Netherlands
- 696 16. Gelre Hospitals, Zutphen, The Netherlands
- 697 17. Martini Hospital, Groningen, The Netherlands
- 698 18. Maxima Medical Center, Veldhoven, The Netherlands
- 699 19. Gemini Hospital, Den Helder, The Netherlands
- 700 20. Medical Center Leeuwarden, Leeuwarden, The Netherlands
- 701 21. Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands
- 702 22. Rode Kruis Hospital, Beverwijk, The Netherlands
- 703 23. St. Antonius Hospital, Nieuwegein, The Netherlands
- 704 24. Deventer Hospital, Deventer, The Netherlands
- 705 25. Slingeland Hospital, Doetinchem, The Netherlands
- 706 26. Refaja Hospital, Stads kanaal, The Netherlands
- 707 27. Bethesda Hospital, Hoogeveen, The Netherlands
- 708 28. University Medical Center Groningen, Beatrix Children’s hospital, Groningen, The
709 Netherlands
- 710 29. Haga Hospital – Juliana Children’s Hospital, Den Haag, The Netherlands

- 711 30. Isala Hospital, Zwolle, The Netherlands
- 712 31. Bernhoven Hospital, Uden, The Netherlands
- 713 32. VieCuri Medical Center, Venlo, The Netherlands
- 714 33. Ziekenhuisgroep Twente, Almelo-Hengelo, The Netherlands
- 715 34. Catharina Hospital, Eindhoven, The Netherlands
- 716 35. Reinier de Graaf Gasthuis, Delft, The Netherlands
- 717 36. ETZ Elisabeth, Tilburg, The Netherlands
- 718 37. Scheper Hospital, Emmen, The Netherlands
- 719 38. St. Jansdal Hospital, Hardewijk, The Netherlands
- 720 39. Laurentius Hospital, Roermond, The Netherlands
- 721 40. Isala Diaconessenhuis, Meppel, The Netherlands
- 722 41. Zuyderland Medical Center, Sittard-Geleen, The Netherlands
- 723 42. Westfriesgasthuis, Hoorn, The Netherlands
- 724 43. Medisch Spectrum Twente, Enschede, The Netherlands
- 725 44. St. Franciscus Gasthuis, Rotterdam, The Netherlands 5
- 726 45. Streektziekenhuis Koningin Beatrix, Winterswijk, The Netherlands
- 727 46. Flevo Hospital, Almere, The Netherlands
- 728 47. Zuwe Hofpoort Hospital, Woerden, The Netherlands

729

730 ***Swiss Pediatric Sepsis Study***

731 **Steering Committee:** Luregn J Schlapbach, MD, FCICM 1,2,3 , Philipp Agyeman, MD 1 ,
732 Christoph Aebi, MD 1 , Christoph Berger, MD 1 Luregn J Schlapbach, MD, FCICM 1,2,3 ,
733 Philipp Agyeman, MD 1 , Christoph Aebi, MD 1 , Eric Giannoni, MD 4,5 , Martin Stocker, MD
734 6 , Klara M Posfay-Barbe, MD 7 , Ulrich Heininger, MD 8 , Sara Bernhard-Stirnermann, MD
735 9 , Anita Niederer-Loher, MD 10 , Christian Kahlert, MD 10 , Paul Hasters, MD 11 , Christa
736 Relly, MD 12 , Walter Baer, MD 13 , Christoph Berger, MD 12 **for the Swiss Pediatric**
737 **Sepsis Study**

738 1. Department of Pediatrics, Inselspital, Bern University Hospital, University of Bern,
739 Switzerland

740 2. Paediatric Critical Care Research Group, Mater Research Institute, University of
741 Queensland, Brisbane, Australia

742 3. Paediatric Intensive Care Unit, Lady Cilento Children's Hospital, Children's Health
743 Queensland, Brisbane, Australia

744 4. Service of Neonatology, Lausanne University Hospital, Lausanne, Switzerland

745 5. Infectious Diseases Service, Lausanne University Hospital, Lausanne, Switzerland

746 6. Department of Pediatrics, Children's Hospital Lucerne, Lucerne, Switzerland

747 7. Pediatric Infectious Diseases Unit, Children's Hospital of Geneva, University Hospitals of
748 Geneva, Geneva, Switzerland

- 749 8. Infectious Diseases and Vaccinology, University of Basel Children's Hospital, Basel,
750 Switzerland
- 751 9. Children's Hospital Aarau, Aarau, Switzerland
- 752 10. Division of Infectious Diseases and Hospital Epidemiology, Children's Hospital of
753 Eastern Switzerland St. Gallen, St. Gallen, Switzerland
- 754 11. Department of Neonatology, University Hospital Zurich, Zurich, Switzerland
- 755 12. Division of Infectious Diseases and Hospital Epidemiology, and Children's Research
756 Center, University Children's Hospital Zurich, Switzerland
- 757 13. Children's Hospital Chur, Chur, Switzerland
- 758 ***Liverpool Partner***
- 759 Principal Investigators
- 760 Enitan Carroll¹
- 761 Stéphane Paulus ^{1,2}
- 762 ALDER HEY SERIOUS PAEDIATRIC INFECTION RESEARCH GROUP (ASPIRE) (in
763 alphabetical order):
- 764 Hannah Frederick³ , Rebecca Jennings³ , Joanne Johnston³ , Rhian Kenwright³
- 765 ¹ Department of Clinical Infection, Microbiology and Immunology, University of Liverpool
766 Institute of Infection and Global Health , Liverpool, England
- 767 ² Alder Hey Children's Hospital, Department of Infectious Diseases, Eaton Road, Liverpool,
768 L12 2AP
- 769 ³ Alder Hey Children's Hospital, Clinical Research Business Unit, Eaton Road, Liverpool,
770 L12 2AP
- 771 ***Micropathology Ltd***
- 772 Colin G Fink^{1,2}, Elli Pinnock¹
- 773 ¹ Micropathology Ltd Research and Diagnosis
- 774 ² University of Warwick
- 775 ***Newcastle partner***
- 776 Principle Investigator
- 777 Marieke Emonts^{1,2}
- 778 Co-Investigator
- 779 Rachel Agbeko^{1,3}
- 780 ¹ Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United
781 Kingdom
- 782 ² Paediatric Infectious Diseases and Immunology Department, Newcastle upon Tyne
783 Hospitals Foundation Trust, Great North Children's Hospital, Newcastle upon Tyne, United
784 Kingdom
- 785 ³ Paediatric Intensive Care Unit, Newcastle upon Tyne Hospitals Foundation Trust, Great
786 North Children's Hospital, Newcastle upon Tyne, United Kingdom

787 ***Gambia partner***

788 Suzanne Anderson: Principal Investigator and West African study oversight:
 789 Fatou Secka: Clinical research fellow and study co-ordinator
 790 Additional Gambia site team (consortium members):
 791 Kalifa Bojang: co-PI
 792 Isatou Sarr: Senior laboratory technician
 793 Ngange Kebbeh: Junior laboratory technician
 794 Gibbi Sey: lead research nurse Medical Research Council Clinic
 795 Momodou Saidykhani: lead research nurse Edward Francis Small Teaching Hospital
 796 Fatoumata Cole: Data manager
 797 Gille Thomas: Data manager
 798 Martin Antonio: Local collaborator 7

799 ***Austrian partner***

800 **PI:** Werner Zenz¹

801 **Co-Investigators/Steering committee:**

802 Daniela S. Klobassa¹ , Alexander Binder¹ , Nina A. Schweintzger¹ , Manfred Sagmeister¹

803 ¹ University Clinic of Paediatrics and Adolescent Medicine, Department of General
 804 Paediatrics, Medical University Graz, Austria

805 **Austrian network, participating centres in Austria, Germany, Italy, Serbia, Lithuania,**
 806 **patient recruitment (in alphabetical order):**

807 Hinrich Baumgart¹ , Markus Baumgartner² , Uta Behrends³ , Ariane Biebl⁴ , Robert
 808 Birnbacher⁵ , Jan-Gerd Blanke⁶ , Carsten Boelke⁷ , Kai Breuling³ , Jürgen Brunner⁸ , Maria
 809 Buller⁹ , Peter Dahlem¹⁰ , Beate Dietrich¹¹ , Ernst Eber¹² , Johannes Elias¹³ , Josef
 810 Emhofer² , Rosa Etschmaier¹⁴ , Sebastian Farr¹⁵ , Ylenia Girtler¹⁶ , Irina Grigorow¹⁷ ,
 811 Konrad Heimann¹⁸ , Ulrike Ihm¹⁹ , Zdenek Jaros²⁰ , Hermann Kalhoff²¹ , Wilhelm
 812 Kaulfersch²² , Christoph Kemen²³ , Nina Klocker²⁴ , Bernhard Köster²⁵ , Benno
 813 Kohlmaier²⁶ , Eleni Komini²⁷ , Lydia Kramer³ , Antje Neubert²⁸ , Daniel Ortner²⁹ , Lydia
 814 Pescollerung¹⁶ , Klaus Pfurtscheller³⁰ , Karl Reiter³¹ , Goran Ristic³² , Siegfried Rödl³⁰ ,
 815 Andrea Sellner²⁶ , Astrid Sonnleitner²⁶ , Matthias Sperl³³ , Wolfgang Stelzl³⁴ , Holger Till¹ ,
 816 Andreas Trobisch²⁶ , Anne Vierzig³⁵ , Ulrich Vogel¹² , Christina Weingarten³⁶ , Stefanie
 817 Welke³⁷ , Andreas Wimmer³⁸ , Uwe Wintergerst³⁹ , Daniel Wüller⁴⁰ , Andrew
 818 Zaunschirm⁴¹ , Ieva Ziuraite⁴² , Veslava Žukovskaja⁴²

819 ¹ Department of Pediatric and Adolescence Surgery, Division of General Pediatric Surgery,
 820 Medical University Graz, Austria

821 ² Department of Pediatrics, General Hospital of Steyr, Austria

822 ³ Department of Pediatrics/Department of Pediatric Surgery, Technische Universität
 823 München (TUM), Munich, Germany

824 ⁴ Department of Pediatrics, Kepler University Clinic, Medical Faculty of the Johannes Kepler
 825 University, Linz, Austria

826 ⁵ Department of Pediatrics and Adolescence Medicine LKH Villach, Austria

- 827 6 Department of Pediatrics and Adolescent Medicine and Neonatology, Hospital
828 Ludmillerstift, Meppen, Germany
- 829 7 Hospital for Children's and Youth Medicine, Oberschwabenklinik, Ravensburg, Germany
- 830 8 Department of Pediatrics, Medical University Innsbruck, Austria
- 831 9 Clinic for Paediatrics and Adolescents Medicine, Sana Hanse-Klinikum Wismar, Germany
- 832 10 Departement of Pediatrics, Medical Center Coburg, Germany
- 833 11 University Medicine Rostock, Department of Pediatrics (UKJ), Rostock, Germany
- 834 12 Department of Pulmonology, Medical University Graz, Austria
- 835 13 Institute for Hygiene and Microbiology, University of Würzburg, Germany
- 836 14 Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University
837 Graz, Austria
- 838 15 Department of Pediatric Orthopedics and Adult Foot and Ankle Surgery, Orthopedic
839 Hospital Speising, Vienna, Austria
- 840 16 Department of Paediatrics, Regional Hospital Bolzano, Italy
- 841 17Department of Pediatrics and Adolescent Medicine, General Hospital
842 Hochsteiermark/Leoben, Austria
- 843 18 Department of Neonatology and Paediatric Intensive Care, Children's University Hospital,
844 RWTH Aachen, Germany
- 845 19 Paediatric Intensive Care Unit, Department of Paediatric Surgery, Donauespital Vienna,
846 Austria
- 847 20 Department of Pediatrics, General Public Hospital, Zwettl, Austria
- 848 21 Pediatric Clinic Dortmund, Germany
- 849 22 Department of Pediatrics and Adolescent Medicine, Klinikum Klagenfurt am Wörthersee,
850 Klagenfurt, Austria
- 851 23 Catholic Children's Hospital Wilhelmstift, Department of Pediatrics, Hamburg, Germany
- 852 24 Department of Pediatrics, Krankenhaus Dornbirn, Austria
- 853 25 Children's Hospital Luedenscheid, Maerkische Kliniken, Luedenscheid, Germany
- 854 26 Department of General Paediatrics, Medical University Graz, Austria
- 855 27 Department of Paediatrics, Schwarzwald-Baar-Hospital, Villingen-Schwenningen,
856 Germany
- 857 28 Department of Paediatrics and Adolescents Medicine, University Hospital Erlangen,
858 Germany
- 859 29 Department of Pediatrics and Adolescent Medicine, Medical University of Salzburg,
860 Austria
- 861 30 Paediatric Intensive Care Unit, Medical University Graz, Austria
- 862 31 Dr. von Hauner Children's Hospital, Ludwig-Maximilians- Universitaet, Munich, Germany
- 863 32 Mother and Child Health Care Institute of Serbia, Belgrade, Serbia

- 864 33 Department of Pediatric and Adolescence Surgery, Division of Pediatric Orthopedics,
865 Medical University Graz, Austria
- 866 34 Department of Pediatrics, Academic Teaching Hospital, Landeskrankenhaus Feldkirch,
867 Austria
- 868 35 University Children's Hospital, University of Cologne, Germany
- 869 36 Department of Pediatrics and Adolescent Medicine Wilheminspital, Vienna, Austria
- 870 37 Department of Pediatric Surgery, Municipal Hospital Karlsruhe, Germany
- 871 38 Hospital of the Sisters of Mercy Ried, Department of Pediatrics and Adolescent Medicine,
872 Ried, Austria
- 873 39 Hospital St. Josef, Braunau, Austria
- 874 40 Christophorus Kliniken Coesfeld Clinic for Pediatrics, Coesfeld, Germany
- 875 41 Department of Paediatrics, University Hospital Krems, Karl Landsteiner University of
876 Health Sciences, Krems, Austria 42Children's Hospital, Affiliate of Vilnius University Hospital
877 Santariskiu Klinikos, Lithuania